Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(11):859-860; doi:10.1093/jnci/dji149
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Albini, A.
Right arrow Articles by Noonan, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albini, A.
Right arrow Articles by Noonan, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Rescuing COX-2 Inhibitors From the Waste Bin

Adriana Albini, Douglas M. Noonan

Affiliations of authors: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy (AA); Università degli studi dell'Insubria, Varese, Italy (DMN)

Correspondence to: Adriana Albini, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi 10, 16132, Genova, Italy (e-mail: adriana.albini@istge.it).

The first 10% of the full text of this article appears below.

COX-2 inhibition has been a main target for new nonsteroidal anti-inflammatory drug (NSAID) development. The effectiveness of two COX-2–specific drugs, Vioxx (rofecoxib) from Merck and Celebrex (celecoxib) from Pfizer, in chronic inflammatory diseases such as arthritis, was so highly promoted that they were among the most prescribed drugs in the category; experimental studies also showed promise in other diseases, including cancer (1). Both drugs have recently met criticism. Vioxx was voluntarily pulled off . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo
Clin. Cancer Res., March 1, 2007; 13(5): 1611 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Dell'Eva, C. Ambrosini, S. Minghelli, D. M. Noonan, A. Albini, and N. Ferrari
The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{kappa}B pathway
Carcinogenesis, February 1, 2007; 28(2): 404 - 413.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Albini, F. Tosetti, R. Benelli, and D. M. Noonan
Tumor Inflammatory Angiogenesis and Its Chemoprevention
Cancer Res., December 1, 2005; 65(23): 10637 - 10641.
[Abstract] [Full Text] [PDF]